NCT05228470 2026-01-06A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.PfizerPhase 2 Completed39 enrolled 15 charts
NCT03744676 2025-02-27A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)Juno Therapeutics, a Subsidiary of CelgenePhase 2 Completed104 enrolled 29 charts
NCT02592876 2019-05-17Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell LymphomaSeagen Inc.Phase 2 Terminated81 enrolled 15 charts
NCT01088815 2019-04-26Hedgehog Inhibitors for Metastatic Adenocarcinoma of the PancreasSidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 2 Completed98 enrolled 14 charts
NCT02855359 2019-03-11Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular LymphomaSeagen Inc.Phase 2 Terminated24 enrolled 10 charts
NCT01177007 2017-08-28Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid TumorsYale UniversityPhase 2 Completed50 enrolled 10 charts
NCT01022996 2016-05-18Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.NovartisPhase 2 Completed57 enrolled 10 charts
NCT00365274 2014-06-02SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell LymphomaNational Cancer Institute (NCI)Phase 2 Terminated6 enrolled 3 charts